Moderna and J&J Covid Vaccination Boosters Have Been Approved by The CDC, Allowing Patients to Mix and Match Injections

Booster Shots Article
SARS-CoV-2 Vaccine Development

Moderna and J&J Covid Vaccination Boosters Have Been Approved by The CDC, Allowing Patients to Mix and Match Injections

The CDC allowed booster shots of Moderna’s and Johnson & Johnson’s Covid-19 vaccines late Thursday, allowing individuals in the U.S. to mix and match any of the three vaccinations approved for use, according to a statement from the agency.

The Advisory Committee on Immunization Practices of the CDC recommended the Moderna booster for older and at-risk persons six months after they finished their primary series of doses, aligning it with Pfizer and BioNTech booster distribution plan. It also recommended J&J boosters for people aged 18 and over who had their first shot at least two months ago.

The CDC did not specify which vaccine should be used as a booster, leaving it up to clinicians or doctors to determine whether to combine doses from different firms to give the best protection for patients.

CDC Director Rochelle Walensky stated, “The data confirms that all three COVID-19 vaccines approved in the United States are safe — as proven by the almost 400 million vaccination doses already provided.” She added even in the middle of the widely circulating Delta variety, they’re all extremely effective in decreasing the likelihood of severe illness, hospitalization, and death.”

According to the CDC, more than 39 million Moderna recipients and over 13 million J&J recipients may be eligible for a booster dosage.

Because many people in the United States and other parts of the region have yet to get even one dose of a vaccine or booster injections, this topic has long been a debatable subject among scientists, both inside and outside the government. The World Health Organization has urged wealthier nations to hold off on providing vaccine boosters, and some experts believe most Americans do not require them at this time.

(Source: CNBC, 2021)

Leave a Reply